> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Medpace Third-Quarter Net Income Rises To $137.5 Million, And Board Approves New Buyback
- URL: https://www.bullished.co/medpace-third-quarter-net-income-rises-to-137-5-million-and-board-approves-new-buyback-a11f8e9f/
- Published: 2026-10-21T20:20:57.000Z
- Updated: 2026-10-28T19:06:54.000Z
- Description: The clinical research firm's revenue, new awards and backlog all grew, and a repurchase plan running through 2028 replaces the old one.
- Author: Matteo Parrino
- Tags: Earnings, MEDP, Industry: Healthcare

[Medpace](https://www.bullished.co/tag/medp/) reported third-quarter [revenue of $716.0 million](https://www.sec.gov/Archives/edgar/data/0001668397/000166839726000034/medp-20261021exx991.htm?ref=bullished.co), up 8.5% from $659.9 million a year earlier, with net income of $137.5 million, or $4.84 per diluted share, versus $111.1 million, or $3.86\. An [8-K filed Wednesday](https://www.sec.gov/Archives/edgar/data/0001668397/000166839726000034/medp-20261020.htm?ref=bullished.co) also shows the board replaced its share repurchase authorization with a new one that runs through December 31, 2028.

## What the results show

Net new business awards, the value of newly signed contracts, were $873.4 million, up 10.6% from $789.6 million a year earlier. Backlog stood at $3,167.2 million on September 30, up 5.6% from $3,000.6 million a year before.

Earnings before interest, taxes, depreciation and amortization (EBITDA, a non-standard profit measure) rose 16.0% to $172.1 million. The margin was 24.0% of revenue versus 22.5% a year earlier. Net income margin was 19.2%, against 16.8%.

For the first nine months, revenue was $2,129.9 million, up 16.9% as reported. Net income for that period was $382.7 million, or $13.37 per diluted share, versus $316.0 million, or $10.64.

Operating cash flow in the quarter was $216.6 million. Cash and equivalents were $705.3 million at September 30, and the company made no share repurchases in the quarter.

## The buyback swap and the forecast

Effective October 20, the board ended the prior authorization, which had $527.0 million left and was due to expire December 31, 2026\. The new one lets management buy back up to $1.0 billion of stock through December 31, 2028, funded from cash on hand.

The filing says the plan sets no minimum purchase, and the board can change, suspend or end it at any time. Purchases can be made on the open market, in private deals or under pre-scheduled trading plans.

For 2026, Medpace forecasts revenue of $2.835 billion to $2.855 billion, growth of 12.0% to 12.8% over 2025's $2.530 billion. It expects net income of $514.0 million to $524.0 million, diluted earnings per share of $17.97 to $18.32, and EBITDA of $638.0 million to $652.0 million.

The forecast assumes 28.6 million diluted weighted average shares and leaves out any repurchases made after September 30.

## What to watch

Management holds a conference call at 9:00 a.m. ET on Thursday, with a supplemental slide presentation posted beforehand.

The call will be the first chance to hear management explain how it plans to use the $1.0 billion authorization.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Medpace Holdings, Inc. (MEDP)](https://www.sec.gov/Archives/edgar/data/0001668397/000166839726000034/medp-20261020.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit medp-20261021exx991.htm — Medpace Holdings, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001668397/000166839726000034/medp-20261021exx991.htm?ref=bullished.co) — SEC EDGAR

### More on Medpace Holdings

- [Medpace's Three Book-To-Bill Shareholder Suits Are Dropped, Then A $1 Billion Buyback Is Approved](https://www.bullished.co/medpaces-three-book-to-bill-shareholder-suits-are-dropped-then-a-1-billion-buyback-is-3337443a/)
- [Medpace Holds Back 2027 Guidance Until February, Says Cancellations Are The Swing Factor](https://www.bullished.co/medpace-holds-back-2027-guidance-until-february-says-cancellations-are-the-swing-factor-9716f8ac/)
- [Medpace CEO August Troendle Sells $30.3 Million In MEDP Stock, Pushing September Total Past $125 Million](https://www.bullished.co/medpace-ceo-august-troendle-sells-30-3-million-in-medp-stock-pushing-september-total-past-e4fb87fc/)

[All Medpace Holdings (MEDP) coverage →](https://www.bullished.co/tag/medp/)